Sam Brusco, Associate Editor02.28.24
Integra LifeSciences announced that Jan De Witte will be retiring as the company’s president and CEO after a successor is named, which the company anticipates by the end of 2024.
The company also revealed that Integra chairman Stuart Essig has been appointed as executive chairman, effective immediately. He has been the company’s non-executive chairman since 2012 and led the company as CEO from 1997 to 2012.
“We are grateful to Jan for his leadership and commitment to Integra and the role he has played in advancing our portfolio and building upon our legacy of innovation,” said Essig. “Jan’s personal decision to retire from Integra and return to Europe follows a leadership tenure marked by significant contributions to the company, including the evolution of our strategy and an expansion of core capabilities. We appreciate Jan’s commitment to a smooth transition and the execution of our roadmap for 2024 and beyond.”
Integra’s board has initiated a search for a new president and CEO and engaged Heidrick & Struggles to support the board in identifying a highly-qualified candidate.
De Witte said, “I am incredibly proud of everything we have accomplished together here at Integra. I am grateful to both the Board for their confidence and trust and the talented workforce at Integra for their ongoing passion and dedication to excellence as we endeavor to restore patients’ lives and set new standards of care. I believe strongly in Integra’s potential for future growth and success. In the meantime, we are squarely focused on delivering our objectives for 2024 through operational execution, particularly in our manufacturing and supply chain.”
The company also revealed that Integra chairman Stuart Essig has been appointed as executive chairman, effective immediately. He has been the company’s non-executive chairman since 2012 and led the company as CEO from 1997 to 2012.
“We are grateful to Jan for his leadership and commitment to Integra and the role he has played in advancing our portfolio and building upon our legacy of innovation,” said Essig. “Jan’s personal decision to retire from Integra and return to Europe follows a leadership tenure marked by significant contributions to the company, including the evolution of our strategy and an expansion of core capabilities. We appreciate Jan’s commitment to a smooth transition and the execution of our roadmap for 2024 and beyond.”
Integra’s board has initiated a search for a new president and CEO and engaged Heidrick & Struggles to support the board in identifying a highly-qualified candidate.
De Witte said, “I am incredibly proud of everything we have accomplished together here at Integra. I am grateful to both the Board for their confidence and trust and the talented workforce at Integra for their ongoing passion and dedication to excellence as we endeavor to restore patients’ lives and set new standards of care. I believe strongly in Integra’s potential for future growth and success. In the meantime, we are squarely focused on delivering our objectives for 2024 through operational execution, particularly in our manufacturing and supply chain.”